UCB to present new bimekizumab data in hidradenitis suppurativa, psoriasis and psoriatic arthritis at EADV 2023.
UCB, a global biopharmaceutical company, announced that it will present new data on bimekizumab at the 32nd European Academy of Dermatology and Venereology (EADV) Congress, October 11–14th in Berlin, Germany
Data will be presented in four oral presentations and 14 posters across a range of diseases including hidradenitis suppurativa (HS), psoriasis and psoriatic arthritis (PsA). Three oral presentations will share bimekizumab data in hidradenitis suppurativa including the first presentation of pooled analyses from the two Phase III studies.
In moderate to severe psoriasis, long-term three-year pooled analyses from five Phase III/IIIb bimekizumab studies in moderate to severe plaque psoriasis will be presented, including the evaluation of maintenance of response in Week 16 responders, and the clinical response in high-impact areas. In addition, there will be the first presentations of bimekizumab real-world data from Germany.
In moderate to severe HS, three oral presentations will share the first analysis of pooled data from the two Phase III studies, BE HEARD I and BE HEARD II, evaluating bimekizumab in the treatment of moderate to severe HS, including an assessment of disease severity over 48 weeks, as measured by the International HS Severity Score System (IHS4), as well as the response across weight and body mass index subgroups.
In the European Union, bimekizumab is approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, for the treatment of adults with active psoriatic arthritis and for the treatment of adults with active axSpA, including non-radiographic axSpA and ankylosing spondylitis, also known as radiographic axSpA. The label information may differ in other countries where approved. Please check local prescribing information. The efficacy and safety of bimekizumab in HS have not been established, and it is not approved for use in this indication by any regulatory authority worldwide.
Specific references to the studies are set out within the appropiate entries in Pharmawand.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.